Patents by Inventor Joseph Anand Reddy

Joseph Anand Reddy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
    Publication number: 20220265841
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Application
    Filed: May 5, 2022
    Publication date: August 25, 2022
    Inventors: Iontcho Radoslavov VLAHOV, Joseph Anand REDDY, Alicia BLOOMFIELD, Ryan DORTON, Melissa NELSON, Marilynn VETZEL, Christopher Paul LEAMON
  • CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
    Publication number: 20210154312
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Application
    Filed: February 2, 2021
    Publication date: May 27, 2021
    Inventors: Iontcho Radoslavov VLAHOV, Joseph Anand REDDY, Alicia BLOOMFIELD, Ryan DORTON, Melissa NELSON, Marilynn VETZEL, Christopher Paul LEAMON
  • CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
    Publication number: 20210154311
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Application
    Filed: February 2, 2021
    Publication date: May 27, 2021
    Inventors: Iontcho Radoslavov VLAHOV, Joseph Anand REDDY, Alicia BLOOMFIELD, Ryan DORTON, Melissa NELSON, Marilynn VETZEL, Christopher Paul LEAMON
  • Conjugates for treating diseases caused by PSMA expressing cells
    Patent number: 10912840
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: February 9, 2021
    Assignee: ENDOCYTE, INC.
    Inventors: Iontcho Radoslavov Vlahov, Joseph Anand Reddy, Alicia Bloomfield, Ryan Dorton, Melissa Nelson, Marilynn Vetzel, Christopher Paul Leamon
  • PBD CONJUGATES FOR TREATING DISEASES
    Publication number: 20200323991
    Abstract: The present disclosure relates to pyrrolobenzodiazepine (PBD) prodrugs and conjugates thereof. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making and methods of using the same.
    Type: Application
    Filed: March 29, 2017
    Publication date: October 15, 2020
    Inventors: Iontcho Radoslavov VLAHOV, Christopher Paul LEAMON, Longwu QI, Ning ZOU, Kevin Yu WANG, Albert E. FELTEN, Garth L. PARHAM, Fei YOU, Hari Krishna R. SANTHAPURAM, Spencer J. HAHN, Joseph Anand REDDY, Yingjuan J. LU, Leroy W. WHEELER, II
  • FOLATE CONJUGATE FOR USE IN TARGETING TUMOR ASSOCIATED MACROPHAGES
    Publication number: 20200038514
    Abstract: Methods are provided for treating cancers using a conjugate herein described as Conjugate 5, or a pharmaceutically acceptable salt thereof. Methods for treating cancers using Conjugate 5, or a pharmaceutically acceptable salt thereof, to target tumor associated macrophages are also described.
    Type: Application
    Filed: September 14, 2017
    Publication date: February 6, 2020
    Inventors: Iontcho Radoslavov VLAHOV, Christopher Paul LEAMON, Longwu QI, Ning ZOU, Kevin Yu WANG, Albert E. FELTEN, Garth L. PARHAM, Fei YOU, Hari Krishna R. SANTHAPURAM, Spencer J. HAHN, Joseph Anand REDDY, Yingjuan J. LU, Leroy W. WHEELER, II
  • CCK2R-drug conjugates
    Patent number: 10500286
    Abstract: The disclosure provided herein pertains to CCK2R-drug conjugates. In particular, the disclosure pertains to CCK2R-drug conjugates that target the delivery of drugs to a mammalian recipient. Also described are methods of making and using CCK2R-drug conjugates.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: December 10, 2019
    Assignee: Endocyte, Inc.
    Inventors: Garth L. Parham, Melissa Nelson, Marilynn Vetzel, Christina M. Dircksen, Joseph Anand Reddy, Christopher Paul Leamon, Iontcho Radoslavov Vlahov
  • CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
    Publication number: 20190314515
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Application
    Filed: May 28, 2019
    Publication date: October 17, 2019
    Inventors: Iontcho Radoslavov VLAHOV, Joseph Anand REDDY, Alicia BLOOMFIELD, Ryan DORTON, Melissa NELSON, Marilynn VETZEL, Christopher Paul LEAMON
  • CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
    Publication number: 20180289826
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Application
    Filed: May 25, 2018
    Publication date: October 11, 2018
    Inventors: Iontcho Radoslavov VLAHOV, Joseph Anand REDDY, Alicia BLOOMFIELD, Ryan DORTON, Melissa NELSON, Marilynn VETZEL, Christopher Paul LEAMON
  • CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
    Publication number: 20180271991
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Application
    Filed: June 4, 2018
    Publication date: September 27, 2018
    Inventors: Iontcho Radoslavov VLAHOV, Joseph Anand REDDY, Alicia BLOOMFIELD, Ryan DORTON, Melissa NELSON, Marilynn VETZEL, Christopher Paul LEAMON
  • CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
    Publication number: 20180256733
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Application
    Filed: May 11, 2018
    Publication date: September 13, 2018
    Inventors: Iontcho Radoslavov VLAHOV, Joseph Anand REDDY, Alicia BLOOMFIELD, Ryan DORTON, Melissa NELSON, Marilynn VETZEL, Christopher Paul LEAMON
  • CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
    Publication number: 20180256736
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Application
    Filed: May 11, 2018
    Publication date: September 13, 2018
    Inventors: Iontcho Radoslavov VLAHOV, Joseph Anand REDDY, Alicia BLOOMFIELD, Ryan DORTON, Melissa NELSON, Marilynn VETZEL, Christopher Paul LEAMON
  • CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
    Publication number: 20180256734
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Application
    Filed: May 11, 2018
    Publication date: September 13, 2018
    Inventors: Iontcho Radoslavov VLAHOV, Joseph Anand REDDY, Alicia BLOOMFIELD, Ryan DORTON, Melissa Nelson, Marilynn VETZEL, Christopher Paul LEAMON
  • CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
    Publication number: 20180256737
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Application
    Filed: May 11, 2018
    Publication date: September 13, 2018
    Inventors: Iontcho Radoslavov VLAHOV, Joseph Anand REDDY, Alicia BLOOMFIELD, Ryan DORTON, Melissa Nelson, Marilynn VETZEL, Christopher Paul LEAMON
  • CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
    Publication number: 20180256735
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Application
    Filed: May 11, 2018
    Publication date: September 13, 2018
    Inventors: Iontcho Radoslavov VLAHOV, Joseph Anand REDDY, Alicia BLOOMFIELD, Ryan DORTON, Melissa Nelson, Marilynn VETZEL, Christopher Paul LEAMON
  • CCK2R-DRUG CONJUGATES
    Publication number: 20180228909
    Abstract: The disclosure provided herein pertains to CCK2R-drug conjugates. In particular, the disclosure pertains to CCK2R-drug conjugates that target the delivery of drugs to a mammalian recipient. Also described are methods of making and using CCK2R-drug conjugates.
    Type: Application
    Filed: August 10, 2016
    Publication date: August 16, 2018
    Inventors: Garth L. PARHAM, Melissa NELSON, Marilynn VETZEL, Christina M. DIRCKSEN, Joseph Anand REDDY, Christopher Paul LEAMON, Iontcho Radoslavov VLAHOV
  • TUBULYSIN CONJUGATE FOR USE IN TREATING CANCER
    Publication number: 20170348376
    Abstract: The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating folate receptor-expressing cancers with a folate-tubulysin conjugate. The invention described herein also relates to methods of treating folate-expressing cancers with a folate tubulysin conjugate in patients where stable disease results after treatment with the folate-tubulysin conjugate.
    Type: Application
    Filed: June 1, 2017
    Publication date: December 7, 2017
    Inventors: Christopher Paul LEAMON, Joseph Anand REDDY, Binh NGUYEN, Alicia BLOOMFIELD, Melissa NELSON, Ryan DORTON
  • METHODS OF TREATING CANCER WITH TUBULYSIN CONJUGATES
    Publication number: 20170290878
    Abstract: The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating folate receptor-expressing cancers with a folate-tubulysin conjugate. The invention described herein also relates to methods of treating folate-expressing cancers with a folate tubulysin conjugate in patients where stable disease results after treatment with the folate-tubulysin conjugate.
    Type: Application
    Filed: September 24, 2015
    Publication date: October 12, 2017
    Inventors: Christopher Paul LEAMON, Joseph Anand REDDY, Binh NGUYEN, Alicia BLOOMFIELD, Melissa NELSON, Ryan DORTON
  • Conjugates for treating diseases caused by PSMA expressing cells
    Patent number: 9782493
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: October 10, 2017
    Assignee: ENDOCYTE, INC.
    Inventors: Iontcho Radoslavov Vlahov, Joseph Anand Reddy, Alicia Bloomfield, Ryan Dorton, Melissa Nelson, Marilynn Vetzel, Christopher Paul Leamon
  • CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
    Publication number: 20170258932
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Application
    Filed: May 26, 2017
    Publication date: September 14, 2017
    Inventors: Iontcho Radoslavov VLAHOV, Joseph Anand REDDY, Alicia BLOOMFIELD, Ryan DORTON, Melissa NELSON, Marilynn VETZEL, Christopher Paul LEAMON